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Background: The accurate identification of a pathogen beyond the species level is critical in epidemiological
studies and investigations of nosocomial outbreaks of infection. The clonal relatedness of 66 multidrug resistant
(MDR) strains of extended spectrum beta-lactamase (ESBL) producing K. pneumoniae isolated from clinical
specimens from hospitalized patients at a Jamaican hospital during a 5 year period were determined by pulsed
field gel electrophoresis (PFGE).
Results: A total 10 different ESBL producing K. pneumoniae genotypes designated Clones I-X were found. The
most frequently occurring strains belonged to Clones I (21/66, 32%), II (15/66, 26%), III (13/66, 20%) and IV (8/66,
12%) which accounted for 86% (57/66) of ESBL producing K. pneumoniae strains over the 5 year period. The
remaining 9 (14%) cases of ESBL producing K. pneumoniae were due to strains of Clones V-X. The 4 predominant
clones persisted for several years in the hospital.
Conclusions: The clonal and temporal distribution of the MDR ESBL producing K. pneumoniae strains among
clinical service areas did not suggest outbreaks of the organism during the period of study. Instead the molecular
epidemiology of ESBL producing K. pneumoniae at this hospital was more representative of an endemic persistence
of clones of the organism with limited dissemination from patient to patient. Further studies to investigate the
factors which determine the emergence and persistence of MDR ESBL producing K. pneumoniae in Jamaican
hospitals and their impact on clinical and economic outcomes at such institutions would be useful.
Background
The increasing prevalence of multidrug resistant (MDR)
pathogens causing nosocomial infection constitutes a
major health problem [1]. Klebsiella pneumoniae ranks
among the top ten organisms causing blood stream
infection, pneumonia and other invasive infections in
hospitalized patients in different countries [2-4]. An
increasing prevalence of multidrug resistant strains of K.
pneumoniae which possess extended spectrum beta-lac-
tamases (ESBL) enzymes, encoded by plasmid-borne
genes which confer resistance to broad spectrum cepha-
losporins and other antibiotics used to treat serious
infection has been widely reported [2]. Multidrug resis-
tance contributes to unfavourable clinical outcomes,
impacts the utilization of hospital resources, increases
the burden of effective infection control practice and
the overall health economic cost [1,2].
The prevalence of ESBL producing strains of K. pneu-
moniae differs between countries. In the developing
world a recent study from Jamaica reported that almost
one-fifth of K. pneumoniae isolates at a tertiary referral
teaching hospital were ESBL producers [5]. The pre-
sence of ESBL-producing Gram negative bacilli in hospi-
tals in other Caribbean islands also has been reported
[6,7].
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T h em a j o r i t yo ft h eM D RK. pneumoniae isolates were
from urine specimens (31/66, 47%), blood (9/66, 13%)
and sputum (7/66, 10%). Almost a third (19/66, 29%)
were isolated from children admitted to paediatric
wards while 15% (10/66) were from intensive care unit
(ICU) patients. The remaining 37 strains were isolated
from patients admitted to medical (n = 15), surgical (n
= 9), special care nursery (n = 5), orthopaedic (n = 5)
and obstetrics/gynaecological services (n = 3).
As shown in Table 1, in addition to ceftazidime, the
majority of the isolates were resistant to trimethoprim/
sulfamethoxazole (59/66, 89%) and the aminoglycosides
(tobramycin 50/66, 76% and gentamicin 49/66, 74%). All
(66/66, 100%) isolates were susceptible to meropenem.
All 66 (100%) isolates of MDR K. pneumoniae tested
positive for ESBL production in the double- disc synergy
test and the E-Test ESBL screen. The E-test ESBL
screen showed that all isolates (66/66; 100%) had MIC
ceftazidime and cefepime > 32 μg/ml and > 16 μg/ml,
respectively. The MICs were subsequently determined
by the agar gel dilution method which revealed MICs
ranging from 32 - >1024 μg/ml for ceftazidime and 2 -
>1024 μg/ml for cefepime indicating ESBL production
by all (66/66; 100%) strains.
The PFGE of XbaI digests of chromosomal DNA from
the 66 ESBL producing K. pneumoniae strains revealed
10 banding patterns representing 10 genotypes which
were designated Clones I-X. The most frequently occur-
ring were Clones I (21/66, 32%), II (15/66, 23%), III (13/
66, 20%) and IV (8/66, 12%). Multiple genotypes in
comparable frequencies were isolated from specimens
from various clinical service areas. The PFGE analysis of
the MDR K. pneumoniae from patients admitted to dif-
ferent clinical service areas and the banding patterns are
shown in Figures 1, 2, 3 and 4. There were 8 cases of
MDR K. pneumoniae infection in long stay patients at
the hospital. Among these, coinfections with multiple
genotypes of MDR K. pneumoniae were observed in 2
admissions in ICU and Paediatrics as shown in Figure 1
(lanes 10 and 11) and Figure 3 (lanes 7 and 8), respec-
tively. Repeat infections occurred in 2 re-admissions
after 3 months and 18 months. In the first case, a differ-
ent clone was involved while in the other the same
clone was identified (shown in Figure 3 lanes 2 and 3).
The temporal distribution of the ESBL producing K.
pneumoniae clones among various hospital services over
the 5 year period is summarized in Table 2. There were
7E S B Lp r o d u c i n gK. pneumoniae isolates during 2000,
12 during 2001, 30 during 2002 and 12 and 5 isolates
during 2003 and 2004, respectively. The MDR ESBL K.
pneumoniae strains belonging to Clones I, II, III and IX
were isolated from patients in 4 different clinical service
areas during 2000. Clones I and II were first identified
in infants on the paediatric wards during July and
August and Clone I in 2 patients on the medical wards
during September of that year. Clones I-IV were present
in the hospital during 2001 with multiple genotypes
occurring in 3 of the 6 clinical service areas. The
increased prevalence of ESBL producing K. pneumoniae
observed in the hospital during 2002 involved strains
belonging to Clones I-IV. However all 7 clinical service
areas were affected but no new genotypes were identi-
fied in that year. In contrast the subsequent decline in
the frequency of isolates during 2003 was accompanied
by the emergence of new genotypes including Clones V-
VIII which were identified in clinical specimens from 3
ICU patients and the reemergence of clone I in the hos-
pital after an absence of 10 months. During 2004 3 of 5
isolates from patients admitted to Surgery and Paedia-
trics belonged to Clone VI.
As shown in Table 3, based on the antibiotic suscept-
ibility testing 13 antibiotypes (R1-R13) were identified.
There were 22 (33%) quinolone-resistant isolates which
were assigned antibiotypes R1-R7. The isolates assigned
antibiotype R1 were resistant to all the quinolones
tested. The remaining 44 isolates were quinolone sensi-
tive and were assigned antibiotypes R8-R13. No correla-
tions were found between the antibiotypes and
genotypic clones of the MDR ESBL producing K. pneu-
moniae. The strains which had similar antibiotypes
often belonged to different PFGE clones. However, all 6
isolates with quinolone-sensitive antibiotypes R9 and
R13 belonged to PFGE Clone 1 as shown in Table 3.
Discussion
The clonal and temporal distributions of the MDR ESBL
producing K. pneumoniae strains among clinical service
areas in the hospital do not suggest outbreaks of the
Table 1 Antibiotic susceptibilities of 66 strains of
multidrug resistant (MDR) extended spectrum beta -
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Page 2 of 8Figure 1 Pulsed field gel electrophoresis (PFGE) analysis of XbaI digests of multidrug resistant (MDR) K. pneumoniae strains from
intensive care unit (ICU) patients (2000-2004). Lane 1: molecular size marker, Saccharomyces cerevisiae; lanes 2-4: MDR K. pneumoniae Clone I
isolated during 2001; lane 5: Clone II isolated during 2002; lanes 6-7: K. pneumoniae strains belonging to Clones III, isolated 2 weeks apart from
the same patient; lanes 8-9: Clones V and VI isolated in 2003; lanes 10-11: Clones VII and VIII, respectively isolated from the same patient during
2003.
Figure 2 Pulsed field electrophoresis (PFGE) analysis of XbaI digests of multidrug resistant (MDR) K. pneumoniae strains isolated from
paediatric patients (2000-2004). Lane 1: molecular size marker, Saccharomyces cerevisiae; lane 2: K. pneumoniae Clone III isolated during 2001;
lanes 3-7: five strains of K. pneumoniae Clone II isolated from specimens collected from the same patient during the same day; lanes 8-9: Clone I
isolated from unrelated patients during 2002; lane 10: Clone II isolated during 2002; lane 11: Clone I isolated during 2003 and lane 12: Clone VI
isolated during 2004.
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Page 3 of 8organism at that institution during the period studied.
Instead the epidemiology of ESBL producing K. pneumo-
niae at this hospital is more representative of an ende-
mic persistence of clones of the organism with limited
dissemination from patient to patient. However, the per-
sistence of related clones over the time period suggests
patient to patient transmission or healthcare worker to
patient transmission. The emergence and reemergence
of Clone I in the ICU during a 6-month period during
2001 is consistent with this concept. Also the results
suggest that there has been transmission of some com-
mon strains including PFGE Clones I, II and III, over
time in the hospital during 2000-2004. This might have
been more evident if asymptomatic patients had been
screened for MDR K. pneumoniae colonization. The
presence of asymptomatically colonized patients may
explain the intermittent appearances of certain strains
over time in various hospital services. The epidemiology
of ESBL producing K. pneumoniae at this hospital
proved complex and, as explained by Branger et al [8],
may involve the spread of self-transferable plasmids as
well as clonal spread [8].
Studies conducted in hospitals elsewhere have reported
the spread of single clones of MDR K. pneumoniae
among patients hospitalized over protracted periods of
time [8,9]. In the present study ESBL producing K. pneu-
moniae strains belonging to Clone III persisted in the
hospital over the 5-year period studied. During 2002 the
year in which the largest number of cases, especially of
paediatric cases, was seen different genotypes of the
organism coexisted in patients on the same wards. This
makes it less clear whether or not outbreaks caused by
single different strains or involving the 4 endemic clones
in the hospital had occurred. The prevalence of ESBL
producers at the University Hospital of the West Indies
for that year was 18% [5]. The factors contributing to the
increasing incidence of ESBL producing K. pneumoniae
during 2002 have not been clearly defined at this hospital
[5]. A number of risk factors for increased colonization
with MDR K. pneumoniae including the use of third gen-
eration cephalosporins have been reviewed [10].
Other interesting observations from the study include
the cases of long stay and repeat patients who remained
colonized or had repeat infections with the same geno-
type after long periods of time and those with concomi-
tant infections with different genotypes of ESBL
producing K. pneumoniae. Branger et al [8] reported the
case of a patient colonized with the same ESBL
Figure 3 Pulsed field electrophoresis (PFGE) analysis of XbaI digests of 11 multidrug resistant (MDR) K. pneumoniae strains isolated
from patients admitted to the paediatric wards (2000-2004). Lane 1: molecular size marker, Saccharomyces cerevisiae; lanes 2-3: two strains
of MDR K. pneumoniae clone I isolated from the same patient during 2001 and 2002, respectively; lane 4: MDR K. pneumoniae clone III isolated
during 2001; lanes 5-6: clone II; lanes 7-8: clones IV and III from the same patient during the same admission in 2002; lanes 9-10: clone IV; and
lanes 11-12: clone I strains from different patients.
Christian et al. BMC Microbiology 2010, 10:27
http://www.biomedcentral.com/1471-2180/10/27
Page 4 of 8producing K. pneumoniae strain for 10 months [8].
Sequential or simultaneous isolation of unrelated strains
of ESBL producing K. pneumoniae from individual
patients has been reported by others [11]. Weller et al
[12] reported that multiple subvariants of a strain could
persist in an infective population without any one sub-
variant becoming dominant [11,12].
T h ep r e v i o u s l yr e p o r t e dd ecreased susceptibility to
aminoglycosides, fluoroquinolones and trimethoprim/
sulfamethoxazole in ESBL producing K. pneumoniae
was also observed in this study [13]. The data on anti-
biotypes provided additional evidence in support of the
clonality of the PFGE genotypes. The predominant
ESBL producing K. pneumoniae genotypes I, II, III and
IV had the quinolone-resistant antibiotype R1. This
might have contributed to the endemic persistence of
these clones in the hospital [14]. The more susceptible
clones were probably not endemic strains at the UHWI
and may have been harboured by patients who were
already colonized on admission [8]. Notably, the PFGE
genotypes V, VII and VIII isolated from ICU patients
also had the more resistant antibiotype R1 though found
in lower numbers. A number of factors including
aggressive antibiotic therapy, prolonged hospitalization
and the performance of invasive procedures are well
documented contributors to the increased risk of infec-
tion with nosocomial strains of MDR K. pneumoniae in
patients admitted to the ICU [15].
Figure 4 Pulsed field electrophoresis (PFGE) analysis of XbaI digests of 9 multidrug resistant (MDR) K. pneumoniae strains (2000-2004).
Isolates were obtained from patients admitted to the orthopaedic ward (lanes 2-6) showing PFGE patterns corresponding to clone IX (lane 2),
clone II (lanes 3 and 5), clone I (lane 4) and clone IV (lane 6), 2000-2002; and the medical wards (lanes 7-10) showing PFGE patterns of clone I
(lanes 7-9) and clone II (lane 10), 2002-2003.
Table 2 Temporal distribution of multidrug resistant (MDR) extended spectrum beta-lactamase (ESBL) producing K.






2000 7 I, II, III, IX Paediatrics, Medicine, Orthopaedics, Obstetrics & Gynaecology
2001 12 I, II, III, IV Intensive care unit, Paediatrics, Surgery, Special Care Nursery, Orthopaedics, Obstetrics &
Gynaecology
2002 30 I, II, III, IV Intensive care unit, Paediatrics, Medicine, Surgery, Special Care Nursery, Orthopaedics
2003 12 I, II, III, IV, V, VI, VII, VIII, X Intensive care unit, Paediatrics, Medicine, Surgery, Special Care Nursery
2004 5 III, IV, VI Paediatrics, Surgery
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Page 5 of 8Clearly different antibiotic susceptibility patterns dis-
tinguish different strains of ESBL producing K. pneumo-
niae as shown in the current study. However, antibiotic
susceptibility testing has relatively limited utility as a
typing system in epidemiologic studies not only because
of phenotypic variation but also because antibiotic resis-
tance is under extraordinary selective pressure in con-
temporary hospitals [14]. The selective pressure from
antimicrobial therapy may alter the antimicrobial sus-
ceptibility profile of an organism, such that related
organisms show different resistance profiles [16]. Graf-
funder et al [10] found a correlation between the selec-
tive pressure of antimicrobial agents identified as risk
factors for ESBL producing organisms and the presence
of related resistance genes residing on the plasmids [10].
Woodford et al [16] also suggests that antibiotic pres-
sure may have been a factor for initial colonization of
patients and the development of further resistance by
the organism [16].
The limitations of the study are those attending stu-
dies involving retrospective data collection, the dispro-
portionately small number of ESBL producing K.
pneumoniae strains from some clinical service areas,
the long time period over which the isolates were col-
lected, the lack of surveillance cultures to detect
asymptomatic, colonized patients with MDR ESBL pro-
ducing K. pneumoniae and the limited available epide-
miologic data to compare with the PFGE typing
results. During the extended period of study advances
in medical technology, changes in patient population,
formulary restrictions and changes in standards of
practice or infection control measures may affect the
results [10].
Conclusions
In summary the results showed clonal diversity of MDR
ESBL producing K. pneumoniae, elements of its tem-
poral distribution which were suggestive of endemic
persistence and dissemination of this organism between
patients at this hospital, the extent of which was not
fully ascertained. Further studies which investigate the
factors which determine the emergence and persistence
of ESBL producing K. pneumoniae in Jamaican hospitals
and the impact on clinical and economic outcomes at
such institutions would be useful.
Methods
Microbiological Investigations
All clinical isolates (n = 66) of MDR K. pneumoniae
from clinical specimens collected from 57 patients
admitted to the University Hospital of the West Indies
(UHWI), Kingston, Jamaica, a tertiary care referral cen-
tre, between June 2000 and April 2004 were stored in
tryptose soy broth at -70°C until required. Standard
microbiological procedures were followed for the differ-
ent clinical specimens [17]. Bacterial isolates were iden-
tified and the initial antibiotic susceptibility testing was
done using the Vitek automated system (Biomerieux,
Durham, North Carolina, U.S.A.). The appropriate anti-
biotic panel for each type of specimen was used as
recommended by the manufacturer. The breakpoints for
antibiotic susceptibility were determined according to
the guidelines of the Clinical and Laboratory Standards
I n s t i t u t e( C L S I )[ 1 7 ] .T h ea ntibiotics tested included
amoxicillin/clavulanic acid, ampicillin, carbenicillin, cefa-
zolin, ceftriaxone, cefuroxime, cephalothin, ceftazidime,
ciprofloxacin, gentamicin, levofloxacin, minocycline,
Table 3 The antibiotypes and pulsed field gel electrophoresis (PFGE) clones of the 66 multidrug resistant (MDR)
extended spectrum beta-lactamase producing (ESBL) K. pneumoniae strains, 2000-2004
Antibiotypes (n)* Resistance Profile † Clones of ESBL K. pneumoniae
R1 (9) NA, Nor, Cip, Lev, Cn, Tob, Min, F, SXT I, II, III, VIII
R2 (1) NA, Nor, Cip, Lev, Cn, Tob, Min, SXT VI
R3 (3) NA, Nor, Cip, Lev, Cn, Tob, SXT III, VII
R4 (3) Lev, Cn, Tob, Min, F, SXT I, II, IV
R5 (5) NA, Cn, Tob, F, SXT I, II
R6 (1) NA, Cn, Tob, SXT II
R7 (1) Lev, F I
R8 (2) Min, Cn I, II
R9 (3) F I
R10 (6) SXT I, II, III, IV, VI
R11 (15) Tob, SXT I, II, III, IV, VI
R12 (14) Cn, Tob, F, SXT I, III, IV, IX, X
R13 (3) Cn, Tob, Min, F, SXT I
* n is the total number of MDR K. pneumoniae assigned to each antibiotype
† NA nalidixic acid, Nor norfloxacin, Cip ciprofloxacin, Lev levofloxacin, Cn gentamicin, Tob tobramycin, Min minocycline, F nitrofurantoin, SXT trimethoprim
sulfamethoxazole
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Page 6 of 8nalidixic acid, nitrofurantoin, norfloxacin, ticarcillin/cla-
vulanic acid, tobramycin, trimethoprim/sulfamethoxa-
zole and meropenem. The MDR strains of K.
pneumoniae were classified as organisms showing resis-
tance to at least three classes of antibiotics including
ceftazidime [18]. Resistance to ceftazidime identified by
Vitek was used as the initial screening test for the pre-
sence of ESBL which was confirmed by E-test (AB Bio-
disk, Solna, Sweden) and double-disc synergy test which
were performed according to the manufacturer’s instruc-
tions and CLSI guidelines [17], respectively. A positive
double disc synergy test was defined as enhancement of
the zones of inhibition for ceftazidime and cefotaxime
in the presence of clavulanic acid.
The MDR ESBL producing K. pneumoniae strains
were assigned antibiotypes based on their resistance
patterns.
Pulsed Field Gel Electrophoresis
Pulsed-field gel electrophoresis (PFGE) was used to
determine the relatedness of the ESBL producing strains
of K. pneumoniae. The PFGE was performed as
described previously with modifications [19]. Electro-
phoresis was carried out in 0.5 × TBE buffer using the
Chef Mapper XA pulsed field electrophoresis system
(Biorad, Hercules, California, U.S.A.). The conditions
were 6 V/cm for 21 h at 12°C, with the pulse time
ramped linearly from 1 s to 40 s. The molecular size
marker included for comparison was Saccharomyces cer-
evisiae (Biorad, Hercules, California, U.S.A.). Following
electrophoresis the gels were stained with ethidium bro-
mide and photographed under ultraviolet light. The
banding patterns were compared based on the criteria
described by Tenover et al [20]. Isolates were considered
indistinguishable if their restriction patterns had the
same number of corresponding bands of the same
apparent size and closely related for differences of 3
bands. Isolates which differed by 4 or more bands were
considered unrelated.
The study was approved by the Ethics Committee in
the Faculty of Medical Sciences of the University of the
West Indies, Mona.
Acknowledgements
We thank Mrs Lois Rainford, Mrs Charmaine Parkes and our colleagues in the
Bacteriology Section of the Microbiology Department, University of the West
Indies for their assistance.
Authors’ contributions
NAC carried out the microbiological and molecular studies and drafted the
manuscript. KRG and MS conceived of the study, participated in its design
and coordination. All authors read and approved the final manuscript.
Received: 10 February 2009
Accepted: 28 January 2010 Published: 28 January 2010
References
1. Blot S, Depuydt P, Vandewoude K, DeBacquer D: Measuring the impact of
multidrug resistance in nosocomial infection. Curr Opin Infect Dis 2007,
20:391-396, Review.
2. Marra AR, Wey SB, Castelo A, Gales AC, Cal RG, Filho JR, Edmond MB,
Pereira CA: Nosocomial bloodstream infections caused by Klebsiella
pneumoniae: impact of extended-spectrum beta-lactamases (ESBL)
production on clinical outcome in a hospital with high ESBL prevalence.
BMC Infect Dis 2006, 6:24.
3. Pfaller MA, Jones RN, Doern GV, Kugler K: Bacterial pathogens isolated
from patients with bloodstream infection: frequencies of occurrence and
antimicrobial susceptibility patterns from the SENTRY antimicrobial
surveillance programme (United States and Canada 1997). Antimicrob
Agents Chemother 1998, 42:1762-1770.
4. Gales AC, Bolmstrom A, Sampaio J, Jones RN, Sader HS: Antimicrobial
susceptibility of Klebsiella pneumoniae producing extende-spectrum
beta-lactamases (ESBL) isolated in hospitals in Brazil. Braz J Infect Dis
1997, 1:196-203.
5. Nicholson AM, Gayle P, Roye-Green K: Extended spectrum beta-lactamase
producing organisms at the University Hospital of the West Indies. West
Indian Med J 2004, 53:104-108.
6. Orett FA: Resistance patterns among selective Gram-negative bacilli from
an intensive care unit in Trinidad West Indies. Saudi Med J 2004,
25:478-483.
7. Del Carmen Rodriguez M, Vera DE, Ramirez-Ronda CH, Saavedra S:
Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in
clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San
Juan Veterans Affairs Medical Center. P R Health Sci J 2004, 23:207-215.
8. Branger C, Lesimple AL, Bruneau B, Berry P, Lambert-Zechovsky N: Long-
term investigation of the clonal dissemination of Klebsiella pneumoniae
isolates producing extended-spectrum b-lactamases in a university
hospital. J Med Microbiol 1998, 47:201-209.
9. Bingen EH, Desjardins P, Arlet G, Bourgeois F, Mariani-Kurkdjian P, Lambert-
Zechovsky NY, Denamur E, Philippon A, Elion J: Molecular epidemiology of
plasmid spread among extended-broad spectrum b-lactamase-
producing Klebsiella pneumoniae isolates in a pediatric hospital. J Clin
Microbiol 1993, 31:179-184.
10. Graffunder EM, Preston KE, Evans AM, Venezia RA: Risk factors associated
with extended- spectrum beta-lactamase-producing organisms at a
tertiary care hospital. J Antimicrob Chemother 2005, 56:139-145.
11. Essack SY, Hall LM, Pillay DG, Mcfadyen ML, Livermore DM: Complexity and
diversity of Klebsiella pneumoniae strains with extended-spectrum b-
lactamases isolated in 1994 and 1996 at a teaching hospital in Durban,
South Africa. Antimicrob Agents Chemother 2001, 45:88-95.
12. Weller TM, MacKenzie FM, Forbes KJ: Molecular epidemiology of a large
outbreak of multiresistant Klebsiella pneumoniae. J Med Microbiol 1997,
46:921-926.
13. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, Mariano N,
Marks S, Burns JM, Dominick D, Lim : Class restriction of cephalosporin
use to control total cephalosporin resistance in nosocomial Klebsiella.
JAMA 1998, 280:1233-1237.
14. Bedenic B, Schmidt H, Herold S, Monaco M, Plecko V, Kalenic S, Katic S,
Skrlin-Subic J: Epidemic and endemic spread of Klebsiella pneumoniae
producing SHV-5 beta-lactamase in Dubrava University Hospital, Zagreb,
Croatia. J Chemother 2005, 17:367-375.
15. Lucet JC, Decré D, Fichelle A, Joly-Guillou ML, Pernet M, Deblangy C,
Kosmann MJ, Régnier B: Control of a prolonged outbreak of extended
spectrum beta-lactamase-producing Enterobacteriaceae in a university
hospital. Clin Infect Dis 1999, 29:1411-1418.
16. Woodford N, Tierno PM Jr, Young K, Tysall L, Palepou MF, Ward E,
Painter RE, Suber DF, Shungu D, Silver LL, Inglima K, Kornblum J,
Livermore D: Outbreak of Klebsiella pneumoniae producing a new
carbapenem-hydrolysing class A beta-lactamase, KPC-3, in a New York
Medical Center. Antimicrob Agents Chemother 2000, 48:4793-4799.
17. Clinical and Laboratory Standards Institute: Performance standards for
antimicrobial disk susceptibility tests Clinical and Laboratory Standards
Institute, Wayne, Pa 2006, Approved standard M2-A9.
18. D’Agata EM: Rapidly rising prevalence of nosocomial multidrug-
resistance, Gram-negative bacilli: a 9-year surveillance stud. Infect Control
Hosp Epidemiol 2004, 25:842-846.
Christian et al. BMC Microbiology 2010, 10:27
http://www.biomedcentral.com/1471-2180/10/27
Page 7 of 819. Birren B, Lai E: Pulsed field gel electrophoresis: a practical guide California:
Academic press 1993.
20. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH,
Swaminathan B: Interpreting chromosomal DNA restriction patterns
produced by pulsed-field gel electrophoresis: criteria for bacterial strain
typing. J Clin Microbiol 1995, 33:2233-2239.
doi:10.1186/1471-2180-10-27
Cite this article as: Christian et al.: Molecular epidemiology of multidrug
resistant extended spectrum beta-lactamase producing Klebsiella
pneumoniae at a Jamaican hospital, 2000 - 2004. BMC Microbiology 2010
10:27.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Christian et al. BMC Microbiology 2010, 10:27
http://www.biomedcentral.com/1471-2180/10/27
Page 8 of 8